A critical evaluation of the Braak staging scheme for Parkinson's disease
- PMID: 19067353
- PMCID: PMC2605160
- DOI: 10.1002/ana.21541
A critical evaluation of the Braak staging scheme for Parkinson's disease
Abstract
Braak and colleagues have proposed that, within the central nervous system, Parkinson's disease (PD) begins as a synucleinopathy in nondopaminergic structures of the lower brainstem or in the olfactory bulb. The brainstem synucleinopathy is postulated to progress rostrally to affect the substantia nigra and cause parkinsonism at a later stage of the disease. In the context of a diagnosis of PD, made from current clinical criteria, the pattern of lower brainstem involvement accompanying mesencephalic synucleinopathy is often observed. However, outside of that context, the patterns of synucleinopathy that Braak described are often not observed, particularly in dementia with Lewy bodies and when synucleinopathy occurs in the absence of neurological manifestations. The concept that lower brainstem synucleinopathy represents "early PD" rests on the supposition that it has a substantial likelihood of progressing within the human lifetime to involve the mesencephalon, and thereby cause the substantia nigra pathology and clinical parkinsonism that have heretofore defined the disease. However, the predictive validity of this concept is doubtful, based on numerous observations made in populations of aged individuals who, despite the absence of neurological signs, have brain synucleinopathy ranging up to Braak stages 4 to 6 at postmortem. Furthermore, there is no relation between Braak stage and the clinical severity of PD. We conclude that the relation between patterns of abnormal synuclein immunostaining in the human brain and the disease entity now recognized as PD remains to be determined.
Figures
Comment in
-
Critical evaluation of the Braak staging scheme for Parkinson's disease.Ann Neurol. 2010 Apr;67(4):550. doi: 10.1002/ana.21638. Ann Neurol. 2010. PMID: 20437592 No abstract available.
Similar articles
-
Patterns and stages of alpha-synucleinopathy: Relevance in a population-based cohort.Neurology. 2008 Mar 25;70(13):1042-8. doi: 10.1212/01.wnl.0000306697.48738.b6. Neurology. 2008. PMID: 18362284
-
Is Braak staging valid for all types of Parkinson's disease?J Neural Transm (Vienna). 2019 Apr;126(4):423-431. doi: 10.1007/s00702-018-1898-9. Epub 2018 Jun 25. J Neural Transm (Vienna). 2019. PMID: 29943229 Review.
-
Lewy body-related alpha-synucleinopathy in the aged human brain.J Neural Transm (Vienna). 2004 Oct;111(10-11):1219-35. doi: 10.1007/s00702-004-0138-7. Epub 2004 Apr 2. J Neural Transm (Vienna). 2004. PMID: 15480835
-
A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders.Biochim Biophys Acta. 2009 Jul;1792(7):730-40. doi: 10.1016/j.bbadis.2008.07.006. Epub 2008 Aug 5. Biochim Biophys Acta. 2009. PMID: 18718530 Review.
-
A critical reappraisal of current staging of Lewy-related pathology in human brain.Acta Neuropathol. 2008 Jul;116(1):1-16. doi: 10.1007/s00401-008-0406-y. Epub 2008 Jul 1. Acta Neuropathol. 2008. PMID: 18592254 Review.
Cited by
-
Alpha Synuclein Toxicity and Non-Motor Parkinson's.Cells. 2024 Jul 27;13(15):1265. doi: 10.3390/cells13151265. Cells. 2024. PMID: 39120295 Free PMC article. Review.
-
The gastrointestinal tract and Parkinson's disease.Front Cell Infect Microbiol. 2024 Jan 15;13:1158986. doi: 10.3389/fcimb.2023.1158986. eCollection 2023. Front Cell Infect Microbiol. 2024. PMID: 38292855 Free PMC article. Review. No abstract available.
-
The Potentiality of Natural Products and Herbal Medicine as Novel Medications for Parkinson's Disease: A Promising Therapeutic Approach.Int J Mol Sci. 2024 Jan 15;25(2):1071. doi: 10.3390/ijms25021071. Int J Mol Sci. 2024. PMID: 38256144 Free PMC article. Review.
-
Cardiac 123I-Metaiodobenzylguanidine (MIBG) Scintigraphy in Parkinson's Disease: A Comprehensive Review.Brain Sci. 2023 Oct 18;13(10):1471. doi: 10.3390/brainsci13101471. Brain Sci. 2023. PMID: 37891838 Free PMC article. Review.
-
Metabolic Brain Changes Can Predict the Underlying Pathology in Neurodegenerative Brain Disorders: A Case Report of Sporadic Creutzfeldt-Jakob Disease with Concomitant Parkinson's Disease.Int J Mol Sci. 2023 Aug 23;24(17):13081. doi: 10.3390/ijms241713081. Int J Mol Sci. 2023. PMID: 37685887 Free PMC article.
References
-
- Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the α-synuclein gene identified in families with Parkinson’s Disease. Science. 1997;276:2045–2047. - PubMed
-
- Spillantini MG, Schmidt ML, Lee VMY, et al. α-Synuclein in Lewy bodies. Nature. 1997;388:839–840. - PubMed
-
- Singleton AB, Farrer M, Johnson J, et al. alpha-Synuclein locus triplication causes Parkinson’s disease. Science. 2003;302:841. - PubMed
-
- Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24:197–211. - PubMed
-
- Braak H, Sastre M, Bohl JR, et al. Parkinson’s disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol. 2007;113:421–429. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical